Int. J. Mol. Sci. 2013, 14(6), 10791-10808; doi:10.3390/ijms140610791

Review
Epigenetic Mechanisms in Penile Carcinoma
Hellen Kuasne 1,2, Fabio Albuquerque Marchi 3, Silvia Regina Rogatto 2,4,* and Ilce Mara de Syllos Cólus 1
1
Department of General Biology, Londrina State University, Londrina, PR 86055-900, Brazil; E-Mails: hellenkuasne@hotmail.com (H.K.); colus@sercomtel.com (I.M.S.C.)
2
International Research and Teaching Center, CIPE, AC Camargo Cancer Center, São Paulo, SP 01508-010, Brazil
3
Inter-institutional Grad Program on Bioinformatics, Institute of Mathematics and Statistics, USP—São Paulo University, São Paulo, SP 05508-090, Brazil; E-Mail: fmarchibr@hotmail.com
4
Department of Urology, Faculty of Medicine, UNESP, Botucatu, SP 18618-970, Brazil
*
Author to whom correspondence should be addressed; E-Mail: rogatto@fmb.unesp.br or silvia.rogatto@cipe.accamargo.org.br; Tel.: +55-11-3811-6436; Fax: +55-11-3811-6271.
Received: 25 March 2013; in revised form: 2 May 2013 / Accepted: 9 May 2013 /
Published: 23 May 2013

Abstract

: Penile carcinoma (PeCa) represents an important public health problem in poor and developing countries. Despite its unpredictable behavior and aggressive treatment, there have only been a few reports regarding its molecular data, especially epigenetic mechanisms. The functional diversity in different cell types is acquired by chromatin modifications, which are established by epigenetic regulatory mechanisms involving DNA methylation, histone acetylation, and miRNAs. Recent evidence indicates that the dysregulation in these processes can result in the development of several diseases, including cancer. Epigenetic alterations, such as the methylation of CpGs islands, may reveal candidates for the development of specific markers for cancer detection, diagnosis and prognosis. There are a few reports on the epigenetic alterations in PeCa, and most of these studies have only focused on alterations in specific genes in a limited number of cases. This review aims to provide an overview of the current knowledge of the epigenetic alterations in PeCa and the promising results in this field. The identification of epigenetically altered genes in PeCa is an important step in understanding the mechanisms involved in this unexplored disease.
Keywords:
penile cancer; epigenetic; DNA methylation; molecular markers

1. Introduction

Penile carcinoma (PeCa), although relatively rare in developed countries of the world, is associated with high morbidity and mortality rates in poor and developing countries. The incidence of PeCa varies among populations, with an incidence rate of 0.58 and 0.84 per 100,000 males in United States and in the Western world, respectively [1,2]. In contrast, this rate is higher in developing countries, ranging from 2.3 to 8 cases per 100,000 men [3]. In Brazil, the incidence rate of penile cancer varies between 2.9 and 6.8 per 100,000 men and represents 2.1% of all cancer cases in men [4,5]. The mean age at presentation of penile cancer is 60 years [6].

The involvement of regional lymph nodes is the best indicator of long-term survival in patients with invasive penile carcinomas [7]. In addition to lymph node metastasis, other pathological factors, including grade, histological type, lymphovascular embolization, and stage and perineural invasion, have been described to be of prognostic value in PeCa [810]. However, none of them can effectively predict outcome.

There is a lack of information regarding the molecular genetic and epigenetic alterations and PeCa. Several studies in other cancer types have focused on epigenetic alterations, and there are promising data from clinical trials regarding the targeting of genes that regulate epigenetic events [11,12]. However, the published studies on PeCa are limited to the evaluation of CpG islands in specific genes.

2. Risk Factors: Human Papillomavirus as One of the Main Actors

Several risk factors have been associated with the development of malignant penile lesions. The most important risk factors are the presence of phimosis [13], poor genital hygiene [14], tobacco usage [15], and human papillomavirus (HPV) infection [16].

A history of phimosis is found in approximately 25% of penile cancer patients [2,17] and is strongly associated with invasive PeCa [17,18]. While circumcision shortly after birth is a protective factor, it does not have the same protective potential when carried out later in life [19]. The lack of circumcision, together with poor genital hygiene, contributes to the accumulation of smegma (which forms from desquamated epithelial cells) and consequently to the risk of developing PeCa [14]. The treatment of psoriasis patients with psoralen and ultraviolet A photo chemotherapy has also been identified as a risk factor for PeCa [20].

Human papillomavirus infection has been reported to have an important role in the development of a subset of PeCa, and its presence is thought to be related to the histological type [16]. Basaloid and warty penile cancers are very frequently HPV-positive, ranging from about 80% to 100%. Conversely, viral DNA is only found in a small fraction of verrucous penile carcinomas [20]. High-risk HPVs exert their oncogenic effect by expressing the oncoproteins, E6 and E7, which bind to and inactivate the tumor suppressor proteins, p53 and Rb, respectively [21].

It has been hypothesized that penile squamous cell carcinomas (PeSCC) arise by two distinct etiologic pathways. One is mediated by HPV infection and most likely involves sexual contact. The second occurs via a non-viral pathway and is related to other risk factors, such as poor genital hygiene and the presence of phimosis [22,23]. The incidence of HPV DNA found in penile carcinoma tissue ranges from 15% to 78% and varies according to the population studied, the method of specimen collection, and the protocol used for HPV detection [24].

In general, HPV infection, mainly by the HPV-16 and HPV-18 genotypes, is found in approximately 50% of all PeSCC [16,25] and is associated with multiple sexual partners [26]. Reports have indicated a positive association between the incidence of HPV infection in male sexual partners of women who had been diagnosed with cervical neoplasia [27]. Men vaccinated with the quadrivalent HPV vaccine that protects against HPV 6/11/16/18 have also been shown to have significantly less HPV-associated anogenital infection and PeCa [28].

Epstein-Barr virus (EBV) is another sexually transmitted virus that could be a cofactor in cancer development. The oncogenic potential of EBV is well known in lymphoproliferative disorders, such as Hodgkin’s lymphoma, Burkitt’s lymphoma, and lymphoma in immune compromised individuals [29]. The association between EBV and HPV has also been suggested in cervical cancer [30]. EBV is one of the most efficient cellular growth-transforming viruses known, and it has been found frequently in the genital mucosa, urethral discharges, and genital ulcers. In penile cancer, Epstein-Barr virus positivity was found in 46.7% of cases, and more than 23% of the men were co-infected with both HPV and EBV [31].

In addition, a number of other penile conditions have been associated with an increased risk of PeCa, including balanitis xerotica obliterans, Bowen’s disease, erythroplasia of Queyrat, bowenoid papulosis, and giant condyloma [32]. Bowen’s disease, erythroplasia of Queyrat, and bowenoid papulosis are uncommon pre-malignant disorders of the anogenital skin that may be confused with a variety of other lesions. Bowen’s disease has been reported to degenerate into invasive carcinoma in 5% to 10% of cases [33], while erythroplasia of Queyrat has been associated with invasive carcinoma in up to 30% of cases [34]. Penile lichen sclerosus, also known as balanitis xerotica obliterans, is a chronic inflammatory disorder that occurs in men of all ages [35], and which is associated with PeSCC in 4% to 6% of patients [36].

Overall, PeCa seems to be a multifactorial disease with several risk factors, including HPV and EBV infection, phimosis, poor hygiene habits, and tobacco usage. Several penile diseases have also been associated with a higher risk of developing PeCa.

3. Histopathological Data: Involvement of Lymph Nodes as the Major Predictive Factor of Poor Prognosis in Penile Cancer

Penile cancer usually originates in the epithelium of the inner prepuce (21% of cases), and the glans (48% of cases) [37]. Most penile malignancies (95%) are squamous cell carcinomas (SCCs). However, PeSCC represents a heterogeneous group of histopathological entities that differ in terms of morphology, pathogenesis, and prognosis [38]. The most common PeSSC type is the usual, followed by verrucous, papillary, basaloid, sarcomatoid, warty, cuniculatum, pseudohyperplastic, adenosquamous, and acantholytic [39]. The histological subtypes carry different risks of developing metastasis to lymph nodes, with usual SCC having a risk of 56.7% and sarcomatoid carcinoma having a risk of 89% [40].

PeSCC can also be divided into five categories according to its way of growth as follows: superficially spreading, vertical growth, verrucous, multicentric, and mixed [41]. Superficially spreading squamous cell cancers occur most frequently, and lymph node metastasis are present in 42% of cases. Lesions with a deeper vertical growth present with positive lymph nodes in 82% of cases. Multicentric lesions have positive lymph nodes in 33% of cases, whereas verrucous lesions rarely present with metastasis to the lymph nodes [42]. The pattern of growth in PeSCC and the depth of invasion are important prognostic determinants [10]. The histopathological grading is based on the Broder’s system that classifies the tumors in well-differentiated tumors (grade I) to undifferentiated and invasive tumors (grade IV) [43]. Two staging systems are used in penile carcinoma: the Jackson classification [44], and the TNM classification [45].

The presence of metastasis in regional lymph nodes is the main factor predicting an unfavorable prognosis for patients with PeSCC [9]. Palpable inguinal lymphadenopathy is present at diagnosis in 58% of patients (range from 20% to 96%), and metastatic carcinoma in 45% of these patients [37]. In the early stages of the disease, radical inguinal lymphadenectomy has been demonstrated to convey survival benefits [7,46]. However, these surgical techniques are limited by their high rates of morbidity and mortality [47]. Recent studies have shown new surgical techniques that have improved patient survival [48,49].

The prognosis of patients with lymph node metastasis varies according to the number of positive lymph nodes, the presence of uni- or bilateral inguinal extension, pelvic node involvement, and the presence of lymph node capsular involvement [9].

Kattan et al.[50] and Ficarra et al.[51] developed nomograms to predict inguinal lymph node involvement and the five-year cancer-specific survival of PeCa patients. These predictive models of patient outcome integrated the information about inguinal lymph node stage, pathologic tumor thickness, growth pattern, histologic grade, lymphatic and venous embolization, corpora cavernosa infiltration, corpus spongiosum, and urethral infiltration. Although nomograms allow improvements in prognostic accuracy compared with the use of each single variable, their use in clinical practice is potentially limited by the lack of external validation [9].

The studies evaluating the impact of HPV infection on the prognosis of patients with PeCa are controversial. Some studies have found an association between HPV positive infection and poor prognosis [52,53], while others have suggested that HPV status does not influence prognosis in invasive penile carcinoma [5456]. HPV infection has also been related to favorable prognosis, as reported by Lont et al.[57], who showed a five-year cancer-specific survival rate of 92% for HPV-positive and 78% for HPV-negative patients. In the same study, the presence of positive lymph nodes was detected in 71% of HPV-negative cases, compared to 29% of HPV-positive patients.

4. Epigenetic Alterations and Cancer: Emerging Potential Markers of Diagnosis, Prognosis, and Therapy

Epigenetic modifications are potentially reversible alterations in DNA methylation or chromatin that are not associated with changes in the DNA sequence. These modifications specify functional outputs from the DNA template and are often heritable through cell division [5861]. The epigenetic regulatory mechanisms are comprised of DNA methylation, histone modifications, and transcriptional alterations induced by noncoding RNAs. Aberrant epigenetic regulation can lead to alterations in global gene expression and genomic instability, which have been shown to have clear implications in the development of cancer [62].

DNA methylation changes include locus-targeted hypermethylation and global hypomethylation [63,64]. DNA methylation is catalyzed by a family of enzymes called DNA methyltransferases (DNMTs). These enzymes transfer a methyl group, donated by S-adenosylmethionine (SAM), to the fifth position carbon of cytosine. Three catalytically active DNMTs, DNMT1, DNMT3A, and DNMT3B are described in the mammals genome [65].

In mammals, DNA methylation primarily occurs by the covalent modification of cytosine residues in CpG dinucleotides. CpG dinucleotides are not evenly distributed across the human genome, but they are instead concentrated in short CpG-rich DNA stretches called “CpG islands” and in regions of large repetitive sequences [6668].

CpG islands are preferentially located at the 5′ end of genes and occupy approximately 60% of human gene promoters [69]. While most of the CpG sites in the genome are methylated, the majority of CpG islands usually remain unmethylated during development and in differentiated tissues. However, some CpG island promoters become methylated during cancer development and progression. In contrast, the repetitive genomic sequences, retrotransposons, introns, and gene deserts, which are scattered throughout the human genome, become unmethylated during tumorigenesis. The global hypomethylation of these DNA regions during cancer development leads to increased genomic instability and results in chromosomal rearrangement [67,70].

The investigation of aberrant CpG island methylation has primarily been carried out using a candidate gene approach [71]. Several methods can be used to determine methylation patterns [67], including methylation-specific polymerase chain reaction (MSP) [72], MethyLight [73], combined bisulfite restriction analysis (COBRA) [74], methylation-specific single-nucleotide primer extension (MS-SNuPE) [75], methylation sensitive high resolution melting (MS-HRM) [76], and quantitative bisulfite pyrosequencing [77]. The gold standard technique to detect DNA methylation at a specific locus is quantitative bisulfite pyrosequencing, which analyzes bisulfite-modified and PCR-amplified DNA and provides information on the methylation status of individual CpG sites [77].

A large number of techniques are available for studying global DNA methylation. Genome-wide approaches can be broadly grouped into three strategies according to how DNA is modified before it is interrogated using microarrays or next generation sequencing platforms. These modifications include bisulfite converted DNA, affinity assays that precipitate methylated DNA (MeDIP and MCIP), and restriction enzyme methods that recognize methylated and unmethylated sequences (CHARM, LUMA, HELP) [7883]. After the initial DNA enrichment or chemical modification, genome-wide analyses can be performed by array hybridization systems, such as the Illumina Infinium and GoldenGate systems (Illumina, Inc., San Diego, CA, USA), or oligonucleotide tiling arrays, such as the Nimblegen (Roche NimbleGen, Madison, WI, USA) and Agilent CpG Islands plus Promoters arrays (Agilent, Santa Clara, CA, USA), pyrosequencers, and next generation sequencing platforms such as Illumina/Solexa, ABI/SOLiD, Roche 454 and Helicos/Single molecule sequencing [84,85]. Although some of these techniques present biases or limitations, they are still useful for interrogating epigenetic marks, especially DNA methylation profiles.

Identifying changes in the methylation profile in tumors allows the identification of molecular markers for diagnosis and prognosis in cancer that could also be translated into therapeutic targets [77]. Wei et al.[86] reported that global hypomethylation was associated with worse prognosis or recurrence after treatment in ovarian cancer patients. In addition, methylation profiles have been demonstrated as important tools for the diagnosis of disease and the prediction of disease progression [8689].

The cytosine methylation in CpG islands at promoter regions provides a stable gene silencing mechanism that plays an important role in regulating gene expression and chromatin architecture. Methylation often occurs in association with histone modifications and other chromatin-associated proteins. Histone proteins, which comprise the nucleosome core, contain a globular C-terminal domain and an unstructured N-terminal tail [90]. Post-translational modifications of histone tails determine which regions of the genome are in a transcriptionally active conformation or in a transcriptionally inactive form. The modifications of histone tails include acetylation, methylation, ubiquitylation, phosphorylation, sumoylation, and ribosylation. Each of these modifications regulate key cellular processes, such as transcription, replication, and repair [9193].

Histone modifications can lead to either the activation or the repression of target genes, depending on the specific residues modified and the type of modifications present. Several active and repressive histone modifications have been identified, and these constitute a complex gene regulatory network in cells, which is known as the “histone code” [94]. The importance of epigenetic regulation is highlighted by the disruption of multiple epigenetic marks in various disease states. This is commonly associated with the deregulation of miRNA expression.

miRNAs are small, noncoding RNAs that regulate gene expression at the posttranscriptional level and are critical in many biological processes and cellular pathways [95,96]. miRNA expression profiles of human cancers have been described in several tumors, and the main causes of the aberrant miRNA expression patterns are DNA copy number alterations, the failure of miRNA post-transcriptional regulation, and genetic mutation or transcriptional silencing associated with the hypermethylation of CpG island promoters [96101]. Recent studies have identified a number of miRNAs as potential biomarkers of diagnosis and prognosis, as well as targets for cancer therapy [102].

In recent years, remarkable progress has been made in target identification, drug discovery, and clinical validation for epigenetic therapeutics [103]. Inhibitors of two classes of epigenetic enzymes, i.e., DNA methyltransferases (DNMTs) and histone deacetylases (HDACs), have already demonstrated utility as molecularly targeted chemotherapeutic agents for specific cancers and have received approval for these indications [11]. Furthermore, a database called HEMD (Human Epigenetic Enzyme & Modulator Database), which integrates human epigenetic enzymes and their modulators, has been developed to facilitate the investigation of epigenetic mechanisms and to provide subsidies for novel drug design [104].

Epigenetic alterations are present in all steps of cancer development and progression. With the improvement of techniques in the epigenetic field, especially those identifying global profiles, potential markers for diagnosis, prognosis and therapy have emerged for a series of tumors. Large-scale studies were also important in improving the knowledge about the mechanisms involved in several cancers. However, there is a lack of information regarding both genetic and epigenetic factors that are involved in PeCa.

5. Epigenetics Studies in PeCa

To the best of our knowledge, there are eight studies in the literature describing epigenetic alterations in PeCa [105112], most of which evaluated the methylation pattern of CpG islands in specific genes (Table 1). Six of these studies investigated the CpG island status of CDKN2A. The CDKN2A locus encodes two tumor suppressor proteins, p16INK4A and p14ARF, which control cell growth through the Rb-CDK4 and p53 pathways, respectively [113]. The tumor suppressor gene CDKN2A blocks the cyclin-dependent kinases 4 and 6, which are involved in the activation of the cell cycle and the inhibition of CDK-mediated phosphorylation of the RB gene. Furthermore, the epigenetically mediated loss of CDKN2A is one of the most common and earliest events in human cancers [114].

Considering all studies of methylation in PeCa, the promoter of CDKN2A has been globally investigated in 183 cases, and its methylation levels vary from 0% to 42% (Table 1). Reports with a larger number of individuals also presented a higher frequency of CDKN2A methylation [105,108,112]. Three studies evaluated the same CpG island and an amplicon with 150 bp [106,108,112] (Figure 1). Two of these studies found similar frequencies of methylation [108,112] (Table 1); however, Soufir et al.[106] reported 0% of methylation level. The low frequency detected by these authors may be related to the small number of invasive carcinomas studied (3 samples) or to HPV infection, which was found in two out of three PeCa samples. The CDKN2A primer sequences were not available in other studies [105,109,110].

Ferreux et al.[105] suggested at least three plausible mechanisms that could be involved in the disruption of the p16INK4A/cyclinD/Rb pathway during penile carcinogenesis, specifically, high-risk HPV infection, CDKN2A promoter methylation and BMI-1 overexpression, which is an alternative mechanism that down-regulates p16INK4A[115]. A significant overexpression of BMI-1 was detected in tumors without methylation of the CDKN2A gene promoter. The data revealed that strong p16INK4A immunostaining was significantly associated with carcinomas positive for high-risk HPV. In addition, the frequency of CDKN2A promoter methylation was higher in HPV-negative tumors than in positive cases. According to Guerrero et al.[108], the hypermethylation of CDKN2A was correlated with negative and weak expression of the p16 protein, and all of the HPV-negative cases had weak or no p16 expression. The difference in p16 expression and the methylation patterns of CDKN2A between HPV positive and negative cases reinforce the hypothesis that PeCa is etiologically heterogeneous and may develop by distinct pathways. Furthermore, in other squamous cell carcinomas, there is evidence that differences in HPV status can lead to different tumor behavior and patient prognosis [116,117].

Poetsch et al.[112] investigated the effect of loss of heterozygosity (LOH), immunohistochemistry, point mutations and promoter methylation of CDKN2A. Fifty percent of primary PeCa showed p16INK4A overexpression, and cases that were negative for p16INK4A expression showed LOH near the CDKN2A locus and/or hypermethylation of the gene promoter. The absence of p16INK4A protein expression, LOH and promoter hypermethylation was significantly associated with the occurrence of lymph node metastasis. While p16 overexpression is almost always associated with the presence of HPV DNA in cervical carcinomas, Poetsch et al.[112] showed that the overexpression of p16INK4A, which is a frequent event in penile carcinomas, occurs in both HPV-positive and HPV-negative cases. The authors suggested that other pathways leading to the coactivation of p53 and p16INK4A that are independent of HPV must be considered because they found the expression of p16INK4A and p53 without the presence of HPV-DNA.

The reported methylation frequencies for RASSF1A varied from 11.5% to 45% (Table 1) [109,110]. Guerrero et al.[108] also investigated the expression of Thrombospondin-1 (TSP-1) and the methylation status of its promoter region. TSP-1 is a cell adhesion glycoprotein secreted by several types of normal cells and by tumor cells [118]. The hypermethylation of the TSP1 gene was associated with unfavorable histological grade, vascular and tumor invasion, weak expression of TSP-1 protein and shorter overall survival. The association of the hypermethylation of TSP1 with poor prognosis makes it a potential marker that could be used to detect more aggressive penile tumors. The methylation pattern of eight genes, i.e., DAPK, FHIT, MGMT, CDKN2A (region p16INK4A and p14ARF), RARβ, RASSF1A, and RUNX3, revealed that at least one of them was methylated in each case [109]. In particular, the tumor suppressor gene, FHIT, and the gene, RUNX3, were methylated in 88% and 42% of the cases, respectively. Subsequently, the authors evaluated the same genes in 25 PeCa cases and included the FHIT protein expression by immunohistochemical staining [110]. Hypermethylation was detected in 92% of the cases, and decreased expression levels of FHIT protein were shown in 88% of cases. Twenty out of the 22 cases negative for FHIT protein expression showed FHIT methylation. Five genes, DAPK, MGMT, CDKN2A, RARβ, and RUNX3, were methylated in more than 20% of the cases. According to the authors, because the methylation of the FHIT gene was more common than the presence of HPV infection, which occurred in less than 5% of patients, this gene might play an important role in the pathogenesis of penile squamous cell carcinoma.

Recently, Rogenhofer et al.[111] evaluated the global methylation levels of the histones, H3K4, H3K9 and H3K27, on a tissue microarray platform containing 65 penile carcinomas, six metastatic lesions, and 30 normal skin samples by immunohistochemistry. A variation in the overall level of histone methylation was detected between normal and tumor samples. The overall levels of H3K4me1, H3K9me1, H3K9me2, H3K27me2, and H3K27me3 were decreased, whereas H3K9me3 levels were increased in PeCa. Hierarchical clustering analysis demonstrated that cancer and normal tissues were differentiated based on the histone methylation pattern of H3K9 and H3K27. A trend towards increased global histone methylation levels was detected in metastasis, and high H3K9me2 levels could be related to poor outcomes in PeCa patients. The epigenetic alterations described in PeCa are summarized in Figure 2.

At present, only a single study has investigated the pattern of methylation of genes in the HPV virus of men with PeCa. According to Kalantari et al.[107] the mechanisms involved in penile carcinogenesis related to HPV infection are similar to those involved in cervical carcinoma. The authors investigated three properties of the HPV genomes in penile carcinomas patients, specifically, the methylation of HPV DNA, the junctions between HPV and cellular DNA, and the genomic variation. The authors found that the HPV16 and 18 L1 genes showed similar patterns of hypermethylation in penile and cervical carcinomas, and as such, the methylation of HPV16 and 18 L1 DNA can serve as a biomarker of integration between HPV and cellular DNA in PeCa.

In summary, a substantial variability of methylation has been described for CDKN2A and RASSF1A in PeCa. Additionally, gene silencing through CpG island hypermethylation and FHIT downregulation have been suggested as potential markers in PeCa. Although several genes have been described to be epigenetically regulated in PeCa, the available data are limited, and only a few reports have confirmed the analysis using gene or protein expression.

6. Future Perspectives and Direction

It has been established that epigenetic changes are critical for the development and progression of several tumors. The majority of studies regarding epigenetic alterations in PeCa have only evaluated the patterns of specific genes. However, the assessment of relevant markers for this disease requires methods that detect alterations in methylation on a genome-wide level. Large-scale studies in PeCa are needed to better comprehend tumor behavior and to determine the molecular markers involved in this disease. In a recent review in penile cancer, Sonpavde et al.[119] emphasized the importance of a better understanding of the basic biology of PeCa to guide the design of clinical trials. In our opinion, given the significant number of PeCa cases that are positive for HPV and EBV infections, it is a necessity to investigate epigenetic alterations based on these patterns using more robust, genome-wide methods. These studies may identify new molecular markers that could be useful for designing effective therapeutic strategies against this clinically and psychologically aggressive disease.

Acknowledgments

The authors would like to thank the National Council of Technological and Scientific Development (CNPq), Coordination for the Improvement of Higher Level Personnel (CAPES) and Fundação de Amparo a Pesquisa do Estado de São Paulo (FAPESP: 2010/51601-6 and 2009/52088-3). Authors would like to thank Cláudia A. Rainho for her critical review and support with the figures.

Conflict of Interest

The authors declare no conflict of interest.

References

  1. Parkin, D.; Whelan, S.; Ferlay, J.; Teppo, L.; Thomas, D. Cancer Incidence in Five Continents; IARC Scientific Publications: Lyon, France, 2002; Volume VIII.
  2. Barnholtz-Sloan, J.S.; Maldonado, J.L.; Pow-sang, J.; Giuliano, A.R.; Guiliano, A.R. Incidence trends in primary malignant penile cancer. Urol. Oncol 2007, 25, 361–367.
  3. Misra, S.; Chaturvedi, A.; Misra, N.C. Penile carcinoma: A challenge for the developing world. Lancet Oncol 2004, 5, 240–247.
  4. Solsona, E.; Algaba, F.; Horenblas, S.; Pizzocaro, G.; Windahl, T.; Urology, E.A.O. Eau guidelines on penile cancer. Eur. Urol 2004, 46, 1–8.
  5. Favorito, L.A.; Nardi, A.C.; Ronalsa, M.; Zequi, S.C.; Sampaio, F.J.; Glina, S. Epidemiologic study on penile cancer in Brazil. Int. Braz. J. Urol 2008, 34, 587–591.
  6. Daling, J.R.; Madeleine, M.M.; Johnson, L.G.; Schwartz, S.M.; Shera, K.A.; Wurscher, M.A.; Carter, J.J.; Porter, P.L.; Galloway, D.A.; McDougall, J.K.; et al. Penile cancer: Importance of circumcision, human papillomavirus and smoking in in situ and invasive disease. Int. J. Cancer 2005, 116, 606–616.
  7. Ornellas, A.A.; Kinchin, E.W.; Nóbrega, B.L.; Wisnescky, A.; Koifman, N.; Quirino, R. Surgical treatment of invasive squamous cell carcinoma of the penis: Brazilian national cancer institute long-term experience. J. Surg. Oncol 2008, 97, 487–495.
  8. Calmon, M.F.; Tasso Mota, M.; Vassallo, J.; Rahal, P. Penile carcinoma: Risk factors and molecular alterations. ScientificWorldJournal 2011, 11, 269–282.
  9. Ficarra, V.; Akduman, B.; Bouchot, O.; Palou, J.; Tobias-Machado, M. Prognostic factors in penile cancer. Urology 2010, 76, S66–S73.
  10. Lopes, A.; Hidalgo, G.S.; Kowalski, L.P.; Torloni, H.; Rossi, B.M.; Fonseca, F.P. Prognostic factors in carcinoma of the penis: Multivariate analysis of 145 patients treated with amputation and lymphadenectomy. J. Urol 1996, 156, 1637–1642.
  11. Copeland, R.A.; Olhava, E.J.; Scott, M.P. Targeting epigenetic enzymes for drug discovery. Curr. Opin. Chem. Biol 2010, 14, 505–510.
  12. Nebbioso, A.; Carafa, V.; Benedetti, R.; Altucci, L. Trials with “epigenetic” drugs: An update. Mol. Oncol 2012, 6, 657–682.
  13. Dillner, J.; von Krogh, G.; Horenblas, S.; Meijer, C.J. Etiology of squamous cell carcinoma of the penis. Scand. J. Urol. Nephrol. Suppl 2000, 205, 189–193.
  14. Kochen, M.; McCurdy, S. Circumcision and the risk of cancer of the penis. A life-table analysis. Am. J. Dis. Child 1980, 134, 484–486.
  15. Harish, K.; Ravi, R. The role of tobacco in penile carcinoma. Br. J. Urol 1995, 75, 375–377.
  16. Miralles-Guri, C.; Bruni, L.; Cubilla, A.L.; Castellsagué, X.; Bosch, F.X.; de Sanjosé, S. Human papillomavirus prevalence and type distribution in penile carcinoma. J. Clin. Pathol 2009, 62, 870–878.
  17. Tsen, H.F.; Morgenstern, H.; Mack, T.; Peters, R.K. Risk factors for penile cancer: Results of a population-based case-control study in los angeles county (united states). Cancer Causes Control 2001, 12, 267–277.
  18. Madsen, B.S.; van den Brule, A.J.; Jensen, H.L.; Wohlfahrt, J.; Frisch, M. Risk factors for squamous cell carcinoma of the penis—Population-based case-control study in Denmark. Cancer Epidemiol. Biomark. Prev 2008, 17, 2683–2691.
  19. Schoen, E.J.; Oehrli, M.; Colby, C.; Machin, G. The highly protective effect of newborn circumcision against invasive penile cancer. Pediatrics 2000, 105, E36.
  20. Gross, G.; Pfister, H. Role of human papillomavirus in penile cancer, penile intraepithelial squamous cell neoplasias and in genital warts. Med. Microbiol. Immunol 2004, 193, 35–44.
  21. Zur Hausen, H. Papillomaviruses and cancer: From basic studies to clinical application. Nat. Rev. Cancer 2002, 2, 342–350.
  22. Rubin, M.A.; Kleter, B.; Zhou, M.; Ayala, G.; Cubilla, A.L.; Quint, W.G.; Pirog, E.C. Detection and typing of human papillomavirus dna in penile carcinoma: Evidence for multiple independent pathways of penile carcinogenesis. Am. J. Pathol 2001, 159, 1211–1218.
  23. Chaux, A.; Cubilla, A.L. The role of human papillomavirus infection in the pathogenesis of penile squamous cell carcinomas. Semin. Diagn. Pathol 2012, 29, 67–71.
  24. Pascual, A.; Pariente, M.; Godínez, J.M.; Sánchez-Prieto, R.; Atienzar, M.; Segura, M.; Poblet, E. High prevalence of human papillomavirus 16 in penile carcinoma. Histol. Histopathol 2007, 22, 177–183.
  25. Backes, D.M.; Kurman, R.J.; Pimenta, J.M.; Smith, J.S. Systematic review of human papillomavirus prevalence in invasive penile cancer. Cancer Causes Control 2009, 20, 449–457.
  26. Schottenfeld, D.; Beebe-Dimmer, J. Alleviating the burden of cancer: A perspective on advances, challenges, and future directions. Cancer Epidemiol. Biomarkers Prev 2006, 15, 2049–2055.
  27. Rombaldi, R.L.; Serafini, E.P.; Villa, L.L.; Vanni, A.C.; Baréa, F.; Frassini, R.; Xavier, M.; Paesi, S. Infection with human papillomaviruses of sexual partners of women having cervical intraepithelial neoplasia. Braz. J. Med. Biol. Res 2006, 39, 177–187.
  28. Gillison, M.L.; Chaturvedi, A.K.; Lowy, D.R. Hpv prophylactic vaccines and the potential prevention of noncervical cancers in both men and women. Cancer 2008, 113, 3036–3046.
  29. Al-Daraji, W.I.; Smith, J.H. Infection and cervical neoplasia: Facts and fiction. Int. J. Clin. Exp. Pathol 2009, 2, 48–64.
  30. Sasagawa, T.; Shimakage, M.; Nakamura, M.; Sakaike, J.; Ishikawa, H.; Inoue, M. Epstein-barr virus (ebv) genes expression in cervical intraepithelial neoplasia and invasive cervical cancer: A comparative study with human papillomavirus (hpv) infection. Hum. Pathol 2000, 31, 318–326.
  31. Afonso, L.A.; Moyses, N.; Alves, G.; Ornellas, A.A.; Passos, M.R.; Oliveira, L.O.H.; Cavalcanti, S.M. Prevalence of human papillomavirus and epstein-barr virus dna in penile cancer cases from brazil. Mem. Inst. Oswaldo. Cruz 2012, 107, 18–23.
  32. Buechner, S.A. Common skin disorders of the penis. BJU Int 2002, 90, 498–506.
  33. Schellhammer, P.F.; Jordan, G.H.; Robey, E.L.; Spaulding, J.T. Premalignant lesions and nonsquamous malignancy of the penis and carcinoma of the scrotum. Urol. Clin. N. Am 1992, 19, 131–142.
  34. Wieland, U.; Jurk, S.; Weissenborn, S.; Krieg, T.; Pfister, H.; Ritzkowsky, A. Erythroplasia of queyrat: Coinfection with cutaneous carcinogenic human papillomavirus type 8 and genital papillomaviruses in a carcinoma in situ. J. Invest. Dermatol 2000, 115, 396–401.
  35. Val, I.; Almeida, G. An overview of lichen sclerosus. Clin. Obstet. Gynecol 2005, 48, 808–817.
  36. Tasker, G.L.; Wojnarowska, F. Lichen sclerosus. Clin. Exp. Dermatol 2003, 28, 128–133.
  37. Sufrin, G.; Huber, R. Benign and Malignant Lesions of the Penis; J.Y. Gillenwater: St. Louis, MO, USA, 1991; pp. 1997–2042.
  38. Mosconi, A.M.; Roila, F.; Gatta, G.; Theodore, C. Cancer of the penis. Crit. Rev. Oncol. Hematol 2005, 53, 165–177.
  39. Chaux, A.; Velazquez, E.F.; Algaba, F.; Ayala, G.; Cubilla, A.L. Developments in the pathology of penile squamous cell carcinomas. Urology 2010, 76, S7–S14.
  40. Pizzocaro, G.; Algaba, F.; Horenblas, S.; Solsona, E.; Tana, S.; van der Poel, H.; Watkin, N.A. Eau penile cancer guidelines 2009. Eur. Urol 2010, 57, 1002–1012.
  41. Cubilla, A.L.; Velazquez, E.F.; Young, R.H. Epithelial lesions associated with invasive penile squamous cell carcinoma: A pathologic study of 288 cases. Int. J. Surg. Pathol 2004, 12, 351–364.
  42. Cubilla, A.L.; Barreto, J.; Caballero, C.; Ayala, G.; Riveros, M. Pathologic features of epidermoid carcinoma of the penis. A prospective study of 66 cases. Am. J. Surg. Pathol 1993, 17, 753–763.
  43. Lucia, M.S.; Miller, G.J. Histopathology of malignant lesions of the penis. Urol. Clin. N. Am 1992, 19, 227–246.
  44. Jackson, S.M. The treatment of carcinoma of the penis. Br. J. Surg 1966, 53, 33–35.
  45. Sobin, L.; Wittekind, C. TNM Classification of Malignant Tumours, 6th ed. ed.; Wiley-Liss: New York, NY, USA, 2002.
  46. Kroon, B.K.; Horenblas, S.; Lont, A.P.; Tanis, P.J.; Gallee, M.P.; Nieweg, O.E. Patients with penile carcinoma benefit from immediate resection of clinically occult lymph node metastases. J. Urol 2005, 173, 816–819.
  47. Ravi, R. Morbidity following groin dissection for penile carcinoma. Br. J. Urol 1993, 72, 941–945.
  48. Britto, C.A.; Rebouças, R.B.; Lopes, T.R.; Silva da Costa, T.; Leite, R.E.C.; de Carvalho, P.S. Video-assisted left inguinal lymphadenectomy for penile cancer. Int. Braz. J. Urol 2012, 38, 289.
  49. Canter, D.J.; Dobbs, R.W.; Jafri, S.M.; Herrel, L.A.; Ogan, K.; Delman, K.A.; Master, V.A. Functional, oncologic, and technical outcomes after endoscopic groin dissection for penile carcinoma. Can. J. Urol 2012, 19, 6395–6400.
  50. Kattan, M.W.; Ficarra, V.; Artibani, W.; Cunico, S.C.; Fandella, A.; Martignoni, G.; Novara, G.; Galetti, T.P.; Zattoni, F.; Members, G.P.C.P. Nomogram predictive of cancer specific survival in patients undergoing partial or total amputation for squamous cell carcinoma of the penis. J. Urol 2006, 175, 2103–2108.
  51. Ficarra, V.; Zattoni, F.; Artibani, W.; Fandella, A.; Martignoni, G.; Novara, G.; Galetti, T.P.; Zambolin, T.; Kattan, M.W. Penile Cancer Project Members. Nomogram predictive of pathological inguinal lymph node involvement in patients with squamous cell carcinoma of the penis. J. Urol. 2006, 175, 1700–1704.
  52. Gregoire, L.; Cubilla, A.L.; Reuter, V.E.; Haas, G.P.; Lancaster, W.D. Preferential association of human papillomavirus with high-grade histologic variants of penile-invasive squamous cell carcinoma. J. Natl. Cancer Inst 1995, 87, 1705–1709.
  53. Burger, R.A.; Monk, B.J.; Kurosaki, T.; Anton-Culver, H.; Vasilev, S.A.; Berman, M.L.; Wilczynski, S.P. Human papillomavirus type 18: Association with poor prognosis in early stage cervical cancer. J. Natl. Cancer Inst 1996, 88, 1361–1368.
  54. Bezerra, A.L.; Lopes, A.; Santiago, G.H.; Ribeiro, K.C.; Latorre, M.R.; Villa, L.L. Human papillomavirus as a prognostic factor in carcinoma of the penis: Analysis of 82 patients treated with amputation and bilateral lymphadenectomy. Cancer 2001, 91, 2315–2321.
  55. Kirrander, P.; Kolaric, A.; Helenius, G.; Windahl, T.; Andrén, O.; Stark, J.R.; Lillsunde-Larsson, G.; Elgh, F.; Karlsson, M. Human papillomavirus prevalence, distribution and correlation to histopathological parameters in a large swedish cohort of men with penile carcinoma. BJU Int 2011, 108, 355–359.
  56. Zhai, J.P.; Li, M.; Wang, Q.Y.; Wei, D.; Xu, K.X. Correlation of cd82 and htert expressions and hpv infection with penile cancer. Zhonghua Nan Ke Xue 2011, 17, 817–822.
  57. Lont, A.P.; Kroon, B.K.; Horenblas, S.; Gallee, M.P.; Berkhof, J.; Meijer, C.J.; Snijders, P.J. Presence of high-risk human papillomavirus dna in penile carcinoma predicts favorable outcome in survival. Int. J. Cancer 2006, 119, 1078–1081.
  58. Herceg, Z.; Hernandez-Vargas, H. New concepts of old epigenetic phenomena and their implications for selecting specific cell populations for epigenomic research. Epigenomics 2011, 3, 383–386.
  59. Feinberg, A.P.; Ohlsson, R.; Henikoff, S. The epigenetic progenitor origin of human cancer. Nat. Rev. Genet 2006, 7, 21–33.
  60. Jones, P.A.; Baylin, S.B. The epigenomics of cancer. Cell 2007, 128, 683–692.
  61. Feinberg, A.P. Phenotypic plasticity and the epigenetics of human disease. Nature 2007, 447, 433–440.
  62. Willard, S.S.; Koochekpour, S. Regulators of gene expression as biomarkers for prostate cancer. Am. J. Cancer Res 2012, 2, 620–657.
  63. Jovanovic, J.; Rønneberg, J.A.; Tost, J.; Kristensen, V. The epigenetics of breast cancer. Mol. Oncol 2010, 4, 242–254.
  64. Sandoval, J.; Esteller, M. Cancer epigenomics: Beyond genomics. Curr. Opin. Genet. Dev 2012, 22, 50–55.
  65. Bestor, T.H. The DNA methyltransferases of mammals. Hum. Mol. Genet 2000, 9, 2395–2402.
  66. Bird, A. DNA methylation patterns and epigenetic memory. Genes Dev 2002, 16, 6–21.
  67. Takai, D.; Jones, P.A. Comprehensive analysis of CPG islands in human chromosomes 21 and 22. Proc. Natl. Acad. Sci. USA 2002, 99, 3740–3745.
  68. Suzuki, M.M.; Bird, A. DNA methylation landscapes: Provocative insights from epigenomics. Nat. Rev. Genet 2008, 9, 465–476.
  69. Wang, Y.; Leung, F.C. An evaluation of new criteria for CPG islands in the human genome as gene markers. Bioinformatics 2004, 20, 1170–1177.
  70. Rodriguez, J.; Frigola, J.; Vendrell, E.; Risques, R.A.; Fraga, M.F.; Morales, C.; Moreno, V.; Esteller, M.; Capellà, G.; Ribas, M.; et al. Chromosomal instability correlates with genome-wide dna demethylation in human primary colorectal cancers. Cancer Res 2006, 66, 8462–9468.
  71. Dahl, C.; Guldberg, P. DNA methylation analysis techniques. Biogerontology 2003, 4, 233–250.
  72. Herman, J.G.; Graff, J.R.; Myöhänen, S.; Nelkin, B.D.; Baylin, S.B. Methylation-specific PCR: A novel PCR assay for methylation status of CPG islands. Proc. Natl. Acad. Sci. USA 1996, 93, 9821–9826.
  73. Eads, C.A.; Danenberg, K.D.; Kawakami, K.; Saltz, L.B.; Blake, C.; Shibata, D.; Danenberg, P.V.; Laird, P.W. Methylight: A high-throughput assay to measure DNA methylation. Nucleic Acids Res 2000, 28, E32.
  74. Xiong, Z.; Laird, P.W. Cobra: A sensitive and quantitative DNA methylation assay. Nucleic Acids Res 1997, 25, 2532–2534.
  75. Gonzalgo, M.L.; Jones, P.A. Rapid quantitation of methylation differences at specific sites using methylation-sensitive single nucleotide primer extension (ms-snupe). Nucleic Acids Res 1997, 25, 2529–2531.
  76. Wojdacz, T.K.; Dobrovic, A. Methylation-sensitive high resolution melting (ms-hrm): A new approach for sensitive and high-throughput assessment of methylation. Nucleic Acids Res 2007, 35, e41.
  77. Tost, J.; Gut, I.G. DNA methylation analysis by pyrosequencing. Nat. Protoc 2007, 2, 2265–2275.
  78. Mohn, F.; Weber, M.; Schübeler, D.; Roloff, T.C. Methylated DNA immunoprecipitation (medip). Methods Mol. Biol 2009, 507, 55–64.
  79. Irizarry, R.A.; Ladd-Acosta, C.; Carvalho, B.; Wu, H.; Brandenburg, S.A.; Jeddeloh, J.A.; Wen, B.; Feinberg, A.P. Comprehensive high-throughput arrays for relative methylation (charm). Genome Res 2008, 18, 780–790.
  80. Serre, D.; Lee, B.H.; Ting, A.H. Mbd-isolated genome sequencing provides a high-throughput and comprehensive survey of DNA methylation in the human genome. Nucleic Acids Res 2010, 38, 391–399.
  81. Karimi, M.; Johansson, S.; Ekström, T.J. Using luma: A luminometric-based assay for global DNA-methylation. Epigenetics 2006, 1, 45–48.
  82. Oda, M.; Greally, J.M. The help assay. Methods Mol. Biol 2009, 507, 77–87.
  83. Sonnet, M.; Baer, C.; Rehli, M.; Weichenhan, D.; Plass, C. Enrichment of methylated DNA by methyl-CPG immunoprecipitation. Methods Mol. Biol 2013, 971, 201–212.
  84. Ammerpohl, O.; Martín-Subero, J.I.; Richter, J.; Vater, I.; Siebert, R. Hunting for the 5th base: Techniques for analyzing DNA methylation. Biochim. Biophys. Acta 2009, 1790, 847–862.
  85. Brebi-Mieville, P.; Ili-Gangas, C.; Leal-Rojas, P.; Noordhuis, M.G.; Soudry, E.; Perez, J.; Roa, J.C.; Sidransky, D.; Guerrero-Preston, R. Clinical and public health research using methylated dna immunoprecipitation (medip): A comparison of commercially available kits to examine differential DNA methylation across the genome. Epigenetics 2012, 7, 106–112.
  86. Wei, S.H.; Chen, C.M.; Strathdee, G.; Harnsomburana, J.; Shyu, C.R.; Rahmatpanah, F.; Shi, H.; Ng, S.W.; Yan, P.S.; Nephew, K.P.; et al. Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. Clin. Cancer Res 2002, 8, 2246–2252.
  87. Vincent, A.; Omura, N.; Hong, S.M.; Jaffe, A.; Eshleman, J.; Goggins, M. Genome-wide analysis of promoter methylation associated with gene expression profile in pancreatic adenocarcinoma. Clin. Cancer Res 2011, 17, 4341–4354.
  88. De Capoa, A.; Musolino, A.; Della Rosa, S.; Caiafa, P.; Mariani, L.; del Nonno, F.; Vocaturo, A.; Donnorso, R.P.; Niveleau, A.; Grappelli, C. DNA demethylation is directly related to tumour progression: Evidence in normal, pre-malignant and malignant cells from uterine cervix samples. Oncol. Rep 2003, 10, 545–549.
  89. Hernandez-Vargas, H.; Lambert, M.P.; le Calvez-Kelm, F.; Gouysse, G.; McKay-Chopin, S.; Tavtigian, S.V.; Scoazec, J.Y.; Herceg, Z. Hepatocellular carcinoma displays distinct DNA methylation signatures with potential as clinical predictors. PLoS One 2010, 5, e9749.
  90. Luger, K.; Mäder, A.W.; Richmond, R.K.; Sargent, D.F.; Richmond, T.J. Crystal structure of the nucleosome core particle at 2.8 a resolution. Nature 1997, 389, 251–260.
  91. Jenuwein, T.; Allis, C.D. Translating the histone code. Science 2001, 293, 1074–1080.
  92. Kouzarides, T. Chromatin modifications and their function. Cell 2007, 128, 693–705.
  93. Huang, Y.; Nayak, S.; Jankowitz, R.; Davidson, N.E.; Oesterreich, S. Epigenetics in breast cancer: What’s new? Breast Cancer Res 2011, 13, 225.
  94. Linggi, B.E.; Brandt, S.J.; Sun, Z.W.; Hiebert, S.W. Translating the histone code into leukemia. J. Cell Biochem 2005, 96, 938–950.
  95. Krol, J.; Loedige, I.; Filipowicz, W. The widespread regulation of microrna biogenesis, function and decay. Nat. Rev. Genet 2010, 11, 597–610.
  96. Lopez-Serra, P.; Esteller, M. DNA methylation-associated silencing of tumor-suppressor micrornas in cancer. Oncogene 2012, 31, 1609–1622.
  97. Calin, G.A.; Croce, C.M. Microrna-cancer connection: The beginning of a new tale. Cancer Res 2006, 66, 7390–7394.
  98. Thomson, J.M.; Newman, M.; Parker, J.S.; Morin-Kensicki, E.M.; Wright, T.; Hammond, S.M. Extensive post-transcriptional regulation of micrornas and its implications for cancer. Genes Dev 2006, 20, 2202–2207.
  99. Chang, T.C.; Yu, D.; Lee, Y.S.; Wentzel, E.A.; Arking, D.E.; West, K.M.; Dang, C.V.; Thomas-Tikhonenko, A.; Mendell, J.T. Widespread microrna repression by MYC contributes to tumorigenesis. Nat. Genet 2008, 40, 43–50.
  100. Melo, S.A.; Kalluri, R. Molecular pathways: Micrornas as cancer therapeutics. Clin. Cancer Res 2012, 18, 4234–4239.
  101. Yamamoto, H.; Adachi, Y.; Taniguchi, H.; Kunimoto, H.; Nosho, K.; Suzuki, H.; Shinomura, Y. Interrelationship between microsatellite instability and microrna in gastrointestinal cancer. World J. Gastroenterol 2012, 18, 2745–2755.
  102. Cho, W.C. Great potential of mirnas as predictive and prognostic markers for cancer. Expert Rev. Mol. Diagn 2012, 12, 315–318.
  103. Kelly, T.K.; de Carvalho, D.D.; Jones, P.A. Epigenetic modifications as therapeutic targets. Nat. Biotechnol 2010, 28, 1069–1078.
  104. Huang, Z.; Jiang, H.; Liu, X.; Chen, Y.; Wong, J.; Wang, Q.; Huang, W.; Shi, T.; Zhang, J. Hemd: An integrated tool of human epigenetic enzymes and chemical modulators for therapeutics. PLoS One 2012, 7, e39917.
  105. Ferreux, E.; Lont, A.P.; Horenblas, S.; Gallee, M.P.; Raaphorst, F.M.; von Knebel Doeberitz, M.; Meijer, C.J.; Snijders, P.J. Evidence for at least three alternative mechanisms targeting the p16ink4a/cyclin d/rb pathway in penile carcinoma, one of which is mediated by high-risk human papillomavirus. J. Pathol 2003, 201, 109–118.
  106. Soufir, N.; Queille, S.; Liboutet, M.; Thibaudeau, O.; Bachelier, F.; Delestaing, G.; Balloy, B.C.; Breuer, J.; Janin, A.; Dubertret, L.; et al. Inactivation of the cdkn2a and the p53 tumour suppressor genes in external genital carcinomas and their precursors. Br. J. Dermatol 2007, 156, 448–453.
  107. Kalantari, M.; Villa, L.L.; Calleja-Macias, I.E.; Bernard, H.U. Human papillomavirus-16 and -18 in penile carcinomas: DNA methylation, chromosomal recombination and genomic variation. Int. J. Cancer 2008, 123, 1832–1840.
  108. Guerrero, D.; Guarch, R.; Ojer, A.; Casas, J.M.; Ropero, S.; Mancha, A.; Pesce, C.; Lloveras, B.; Garcia-Bragado, F.; Puras, A. Hypermethylation of the thrombospondin-1 gene is associated with poor prognosis in penile squamous cell carcinoma. BJU Int 2008, 102, 747–755.
  109. Yanagawa, N.; Osakabe, M.; Hayashi, M.; Tamura, G.; Motoyama, T. Detection of HPV-DNA, p53 alterations, and methylation in penile squamous cell carcinoma in japanese men. Pathol. Int 2008, 58, 477–482.
  110. Yanagawa, N.; Osakabe, M.; Hayashi, M.; Tamura, G.; Motoyama, T. Frequent epigenetic silencing of the FHIT gene in penile squamous cell carcinomas. Virchows. Arch 2008, 452, 377–382.
  111. Rogenhofer, S.; Miersch, H.; Göke, F.; Kahl, P.; Wieland, W.F.; Hofstädter, F.; Kristiansen, G.; von Ruecker, A.; Müller, S.C.; Ellinger, J. Histone methylation defines an epigenetic entity in penile squamous cell carcinoma. J. Urol 2012, 189, 1117–1122.
  112. Poetsch, M.; Hemmerich, M.; Kakies, C.; Kleist, B.; Wolf, E.; vom Dorp, F.; Hakenberg, O.W.; Protzel, C. Alterations in the tumor suppressor gene p16(ink4a) are associated with aggressive behavior of penile carcinomas. Virchows. Arch 2011, 458, 221–229.
  113. Larsen, C.J. Contribution of the dual coding capacity of the p16ink4a/mts1/cdkn2 locus to human malignancies. Prog. Cell Cycle Res 1997, 3, 109–124.
  114. Kim, W.Y.; Sharpless, N.E. The regulation of ink4/arf in cancer and aging. Cell 2006, 127, 265–275.
  115. Jacobs, J.J.; Kieboom, K.; Marino, S.; DePinho, R.A.; van Lohuizen, M. The oncogene and polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature 1999, 397, 164–168.
  116. Deng, Z.; Hasegawa, M.; Yamashita, Y.; Matayoshi, S.; Kiyuna, A.; Agena, S.; Uehara, T.; Maeda, H.; Suzuki, M. Prognostic value of human papillomavirus and squamous cell carcinoma antigen in head and neck squamous cell carcinoma. Cancer Sci 2012, 103, 2127–2134.
  117. Huang, H.; Zhang, B.; Chen, W.; Zhou, S.M.; Zhang, Y.X.; Gao, L.; Xu, Z.G.; Qiao, Y.L.; Tang, P.Z. Human papillomavirus infection and prognostic predictors in patients with oropharyngeal squamous cell carcinoma. Asian Pac. J. Cancer Prev 2012, 13, 891–896.
  118. Bornstein, P. Thrombospondins as matricellular modulators of cell function. J. Clin. Invest 2001, 107, 929–934.
  119. Sonpavde, G.; Pagliaro, L.C.; Buonerba, C.; Dorff, T.B.; Lee, R.J.; di Lorenzo, G. Penile cancer: Current therapy and future directions. Ann. Oncol 2013, 24, 1179–1189.
Ijms 14 10791f1 200
Figure 1. CpG islands described on CDKN2A gene. Three studies evaluated the same CpG island in an amplicon with 150 bases pair [106,108,112].

Click here to enlarge figure

Figure 1. CpG islands described on CDKN2A gene. Three studies evaluated the same CpG island in an amplicon with 150 bases pair [106,108,112].
Ijms 14 10791f1 1024
Ijms 14 10791f2 200
Figure 2. Epigenetic alterations were described in eight studies of penile carcinoma (PeCa). Aberrant DNA methylation pattern of DAPK, FHIT, MGMT, CDKN2A, RARβ, RASSF1A, TSP-1, and RUNX3 and alteration in the expression levels of histones were events related with this disease. In special, CDKN2A gene was evaluated in six studies.

Click here to enlarge figure

Figure 2. Epigenetic alterations were described in eight studies of penile carcinoma (PeCa). Aberrant DNA methylation pattern of DAPK, FHIT, MGMT, CDKN2A, RARβ, RASSF1A, TSP-1, and RUNX3 and alteration in the expression levels of histones were events related with this disease. In special, CDKN2A gene was evaluated in six studies.
Ijms 14 10791f2 1024
Table 1. Summary of the epigenetics studies in penile carcinomas described in the literature.

Click here to display table

Table 1. Summary of the epigenetics studies in penile carcinomas described in the literature.
ReferencesNumber of samplesMethodGene studied% methylationHPV infectionHPV 16
Ferreux et al.[105]53Methylation-specific PCRCDKN2A9 (17%)20 (38%)15 (28%)
Poetsch et al.[112]52Methylation-specific PCRCDKN2A22 (42%)20 (38%)18 (35%)
Soufir et al.[106]3Methylation-specific PCRCDKN2A0 (0%)2 (66.3%)2 (100%)
Guerreto et al.[108]24Methylation-specific PCRCDKN2A
RASSF1A
TSP-1
9 (38%)
10 (42%)
11 (46%)
11 (46%)10 (42%)
Yanagawa et al.[109]26Methylation-specific PCRDAPK
FHIT
MGMT
CDKN2A (p16INK4A)
CDKN2A (p14ARF)
RARβ
RASSF1A
RUNX3
7 (26.9%)
23 (88.4%)
5 (19.2%)
1 (3.8%)
6 (23.1%)
6 (23.1%)
3 (11.5%)
11 (42.3%)
3 (11.5%)3 (11.5%)
Yanagawa et al.[110]25Methylation-specific PCRDAPK
FHIT
MGMT
CDKN2A (p16INK4A)
CDKN2A (p14ARF)
RARβ
RASSF1A
RUNX3
7 (28%)
23 (92%)
5(20%)
1 (4%)
6 (24%)
6 (24%)
3 (12%)
11 (44%)
3 (12%)3 (12%)
Kalantari et al.[107]24DNA sequencingL1 HPV16
LCR HPV16
58%
22%
24 (100%)19 (79%)
Rogenhofer et al.[111]65ImmunohistochemicalH3K4
H3K9
H3K27
H3K4me1
Decrease
H3K9me1
Decrease
H3K9me2
Decrease
H3K27me2
Decrease
H3K27me3
Decrease
H3K9me3
Increase
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert